AP2015008664A0 - Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) - Google Patents

Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)

Info

Publication number: AP2015008664A0
Authority: AP; ARIPO
Prior art keywords: janus; jak; pyrrolo; inhibitors; pyrimidine derivatives
Prior art date: 2013-02-22

Application number

AP2015008664A

Other languages

English (en)

Inventor

Michael L Vazquez

Rayomand Jal Unwalla

John David Trzupek

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-22

Filing date

2014-02-11

Publication date

2015-08-31

2014-02-11 Application filed by Pfizer filed Critical Pfizer

2015-08-31 Publication of AP2015008664A0 publication Critical patent/AP2015008664A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)

AP2015008664A 2013-02-22 2014-02-11 Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) AP2015008664A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361767947P	2013-02-22	2013-02-22
PCT/IB2014/058889 WO2014128591A1 (fr)	2013-02-22	2014-02-11	Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)

Publications (1)

Publication Number	Publication Date
AP2015008664A0 true AP2015008664A0 (en)	2015-08-31

Family

ID=50151346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008664A AP2015008664A0 (en)	2013-02-22	2014-02-11	Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)

Country Status (47)

Country	Link
US (3)	US9035074B2 (fr)
EP (2)	EP3290421B1 (fr)
JP (2)	JP6145179B2 (fr)
KR (1)	KR101787858B1 (fr)
CN (2)	CN107089985B (fr)
AP (1)	AP2015008664A0 (fr)
AR (1)	AR094857A1 (fr)
AU (1)	AU2014220357B2 (fr)
BR (1)	BR112015019634B1 (fr)
CA (1)	CA2900703C (fr)
CL (1)	CL2015002303A1 (fr)
CR (1)	CR20150395A (fr)
CU (1)	CU24275B1 (fr)
CY (3)	CY1119502T1 (fr)
DK (2)	DK2958921T3 (fr)
DO (1)	DOP2015000206A (fr)
EA (1)	EA027879B1 (fr)
ES (2)	ES2647525T3 (fr)
FR (1)	FR22C1006I2 (fr)
GE (1)	GEP201606600B (fr)
HR (2)	HRP20171599T2 (fr)
HU (3)	HUE041778T2 (fr)
IL (1)	IL240132B (fr)
LT (3)	LT3290421T (fr)
LU (1)	LUC00261I2 (fr)
MA (1)	MA38347A1 (fr)
MD (1)	MD4735C1 (fr)
ME (2)	ME03301B (fr)
MX (1)	MX374338B (fr)
MY (1)	MY177476A (fr)
NL (1)	NL301155I2 (fr)
NO (2)	NO3052752T3 (fr)
NZ (1)	NZ710411A (fr)
PE (1)	PE20151764A1 (fr)
PH (1)	PH12015501779A1 (fr)
PL (2)	PL3290421T3 (fr)
PT (2)	PT3290421T (fr)
RS (2)	RS56503B1 (fr)
SG (1)	SG11201505816UA (fr)
SI (2)	SI2958921T1 (fr)
TN (1)	TN2015000355A1 (fr)
TR (1)	TR201902525T4 (fr)
TW (1)	TWI507408B (fr)
UA (1)	UA111804C2 (fr)
UY (1)	UY35337A (fr)
WO (1)	WO2014128591A1 (fr)
ZA (1)	ZA201505454B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3311666T (pt)	2010-08-18	2021-06-21	Biosplice Therapeutics Inc	Dicetonas e hidroxicetonas como ativadores da via de sinalização de catenina
EP2948134B1 (fr)	2013-01-24	2020-03-04	Palvella Therapeutics, Inc.	Compositions pour une administration transdermique d'inhibiteurs de mtor
EP3456325A3 (fr)	2013-02-22	2019-05-22	Samumed, LLC	Gamma-dicétones en tant qu'activateurs de la voie de signalisation wnt/ -caténine
KR101787858B1 (ko)	2013-02-22	2017-10-18	화이자 인코포레이티드	야누스-관련된 키나아제의 억제제로서의 피롤로 [2,3-d]피리미딘 유도체
ES2750655T3 (es) *	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
CN107106549B (zh)	2014-08-20	2020-06-16	萨穆梅德有限公司	用于治疗和预防老化皮肤和皱纹的γ–二酮
KR102081272B1 (ko) *	2015-05-29	2020-02-25	우시 포춘 파마슈티컬 컴퍼니 리미티드	Janus 키나아제 억제제
US11780848B2 (en)	2015-10-16	2023-10-10	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
JP7096592B2 (ja)	2016-02-16	2022-07-06	ワシントン・ユニバーシティ	Ｊａｋ阻害剤およびこれらの利用
US10722499B2 (en)	2017-01-06	2020-07-28	Palvella Therapeutics, Inc.	Anyhydrous compositions of mTOR inhibitors and methods of use
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
SMT202200134T1 (it)	2018-03-08	2022-05-12	Incyte Corp	Composti di amminopirazindiolo come inibitori di pi3k-y
EP3817743A4 (fr)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
CN112384282B (zh)	2018-07-06	2024-07-02	辉瑞公司	吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途
CA3118488A1 (fr) *	2018-11-05	2020-05-14	Avista Pharma Solutions, Inc.	Composes chimiques
KR102857917B1 (ko) *	2019-01-30	2025-09-10	펠리카메드 바이오테크놀로지 컴퍼니 리미티드	Jak 억제제 및 그 제조 방법
CA3130034C (fr)	2019-02-15	2023-12-19	Pfizer Inc.	Compose de pyrimidinyl-3,8-diazabicyclo [3.2.1] octanylmethanone cristallin et son utilisation
EP3939979A4 (fr)	2019-03-14	2022-04-06	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	Inhibiteur de kinase jak, son procédé de préparation et ses applications dans le domaine de la médecine
WO2020261041A1 (fr) *	2019-06-27	2020-12-30	Glenmark Life Sciences Limited	Procédé pour la préparation d'abrocitinib
US20250032492A1 (en) *	2019-09-11	2025-01-30	Pfizer Inc.	Treatment of hidradenitis with jak inhibitors
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
US20230149407A1 (en)	2020-04-04	2023-05-18	Pfizer Inc.	Methods of Treating Coronavirus Disease 2019
CN113637018A (zh)	2020-04-27	2021-11-12	苏州晶云药物科技股份有限公司	磺酰胺类化合物的晶型及其制备方法
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN115667263A (zh) *	2020-05-28	2023-01-31	辉瑞公司	吡咯并[2,3-d]嘧啶衍生物
TW202227434A (zh) *	2020-09-08	2022-07-16	瑞士商葛德瑪控股公司	新穎jak抑制劑化合物、其合成方法及其用途
CA3191598A1 (fr) *	2020-09-11	2022-03-17	Gilles Ouvry	Nouveaux composes inhibiteurs de jak, leur procede de synthese et leur utilisation
JP2024505910A (ja)	2021-02-02	2024-02-08	ファイザー・インク	慢性手湿疹の処置のための投与レジメン
WO2023014049A1 (fr) *	2021-08-02	2023-02-09	한국화학연구원	Nouveau dérivé de pyrrolopyrimidine, son procédé de préparation et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement d'une maladie hépatique métabolique
CN118255769A (zh) *	2022-12-28	2024-06-28	格格巫（珠海）生物科技有限公司	一种立体异构体的制备方法及中间体
ES2993658B2 (es)	2023-06-27	2025-07-02	Moehs Iberica Sl	(3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (fr)	2023-07-06	2025-01-09	Pfizer Ireland Pharmaceuticals	Procédé de fabrication amélioré et intermédiaires pour un composé pyrrolo[2,3-d]pyrimidine et leur utilisation
ES3040374A1 (es)	2024-04-30	2025-10-30	Moehs Iberica Sl	Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en)	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
EP0674641B1 (fr)	1992-12-17	1999-03-03	Pfizer Inc.	Pyrrolopyrimidines en tant qu'antagonistes du facteur liberateur de corticotrophine (crf)
JPH06329675A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH06329674A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH08134068A (ja)	1994-11-02	1996-05-28	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en)	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
AU3951899A (en)	1998-06-19	2000-01-05	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (fr)	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4808300A (en)	1999-04-30	2000-11-17	Neurogen Corporation	9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
DE60037345T2 (de)	1999-12-10	2008-11-13	Pfizer Products Inc., Groton	Pyrrolo(2,3-d)pyrimidin-Verbindungen
DE60118521T2 (de)	2000-01-07	2006-10-12	Universitaire Instelling Antwerpen	Purin derivate, ihre herstellung und verwendung
AU784297C (en)	2000-06-26	2007-01-11	Pfizer Products Inc.	Pyrrolo(2,3-d)pyrimidine compounds as immunosuppressive agents
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
EP2050751A1 (fr)	2001-11-30	2009-04-22	OSI Pharmaceuticals, Inc.	Composés spécifiques aux récepteurs A1 et A3 de l'adénosine et leur utilisation
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (fr)	2002-10-04	2004-04-22	Merck & Co., Inc.	Inhibiteurs de thrombine
CN101353321A (zh)	2002-11-21	2009-01-28	辉瑞产品公司	3-氨基-哌啶衍生物及其制备方法
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ565363A (en) *	2005-07-29	2010-03-26	Pfizer Prod Inc	Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
EP2007373A4 (fr)	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	Inhibition de la toxicité de l'alpha-synucléine
WO2008089310A2 (fr)	2007-01-18	2008-07-24	Lexicon Pharmaceuticals, Inc.	Méthodes et compositions utilisées dans le traitement de troubles corporels
US20080194557A1 (en)	2007-01-18	2008-08-14	Joseph Barbosa	Methods and compositions for the treatment of pain, inflammation and cancer
BRPI0820342A2 (pt)	2007-11-07	2015-05-26	Foldrx Pharmaceuticals Inc	Modulação de tráfego de proteína
JP2011503046A (ja)	2007-11-08	2011-01-27	ファイザー・インク	シクロブチルカルボン酸誘導体
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
PT2384326E (pt) *	2008-08-20	2014-06-09	Zoetis Llc	Compostos de pirrolo[2,3-d]pirimidina
BRPI0918935A2 (pt)	2008-09-18	2015-12-01	Pfizer Ltd	compostos amida úteis em terapia
CN102574860A (zh) *	2009-10-15	2012-07-11	辉瑞大药厂	吡咯并[2,3-d]嘧啶化合物
SG10201407976UA (en)	2009-12-01	2015-01-29	Abbvie Inc	Novel tricyclic compounds
ES2461967T3 (es) *	2009-12-18	2014-05-21	Pfizer Inc.	Compuestos de pirrolo[2,3-d]pirimidina
EP2523957A1 (fr)	2010-01-12	2012-11-21	F. Hoffmann-La Roche AG	Composés hétérocycliques tricycliques, leurs compositions et procédés d'utilisation
WO2011104652A2 (fr)	2010-02-24	2011-09-01	Pfizer Inc.	Compositions vétérinaires
WO2012009678A1 (fr)	2010-07-16	2012-01-19	Agios Pharmaceuticals, Inc.	Compositions thérapeutiquement actives et méthode d'utilisation correspondante
WO2012009649A1 (fr)	2010-07-16	2012-01-19	Anderson Gaweco	Inhibiteurs mif et leurs utilisations
RU2606514C2 (ru)	2010-12-03	2017-01-10	Эпизайм, Инк.	Замещенные пуриновые и 7-деазапуриновые соединения
US8987307B2 (en)	2011-03-03	2015-03-24	Hoffmann-La Roche Inc.	3-amino-pyridines as GPBAR1 agonists
KR20140041519A (ko)	2011-06-07	2014-04-04	다이닛본 스미토모 세이야꾸 가부시끼가이샤	인다졸-유도체 및 피롤로피리딘-유도체 및 그의 약제학적 용도
JP2013010719A (ja)	2011-06-30	2013-01-17	Dainippon Sumitomo Pharma Co Ltd	ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
SI2796460T1 (sl) *	2011-12-21	2018-10-30	Jiangsu Hengrui Medicine Co. Ltd	Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
WO2014011911A2 (fr)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Inhibiteurs d'irak et leurs utilisations
RS58242B1 (sr)	2012-07-20	2019-03-29	Zoetis Services Llc	Režim doziranja za inhibitore janus kinaze (jak)
JP2014133739A (ja)	2012-12-12	2014-07-24	Dainippon Sumitomo Pharma Co Ltd	インダゾール誘導体またはピロロピリジン誘導体からなる医薬
KR101787858B1 (ko) *	2013-02-22	2017-10-18	화이자 인코포레이티드	야누스-관련된 키나아제의 억제제로서의 피롤로 [2,3-d]피리미딘 유도체
ES2750655T3 (es)	2014-08-12	2020-03-26	Pfizer	Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa

2014
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active Active
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/fr not_active Ceased
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/fr unknown
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/fr unknown
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/fr active Active
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 CA CA2900703A patent/CA2900703C/fr active Active
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/fr active Active
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-11 MX MX2015010928A patent/MX374338B/es active IP Right Grant
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779A1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTC2958921I2/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active
- 2022-05-13 LU LU00261C patent/LUC00261I2/fr unknown

Also Published As

Publication number	Publication date
PL2958921T3 (pl)	2018-01-31
TN2015000355A1 (fr)	2017-01-03
SI3290421T1 (sl)	2019-03-29
CU24275B1 (es)	2017-10-05
MY177476A (en)	2020-09-16
CY2022003I1 (el)	2022-03-24
CY2022003I2 (el)	2022-03-24
US20150246048A1 (en)	2015-09-03
CN107089985A (zh)	2017-08-25
US20140243312A1 (en)	2014-08-28
JP6145179B2 (ja)	2017-06-07
US9549929B2 (en)	2017-01-24
ES2647525T3 (es)	2017-12-22
NZ710411A (en)	2017-11-24
KR101787858B1 (ko)	2017-10-18
MX2015010928A (es)	2015-10-29
EP2958921B1 (fr)	2017-09-20
PH12015501779B1 (en)	2015-12-02
HRP20190152T1 (hr)	2019-03-22
PL3290421T3 (pl)	2019-05-31
MX374338B (es)	2025-03-06
TWI507408B (zh)	2015-11-11
TR201902525T4 (tr)	2019-03-21
CA2900703A1 (fr)	2014-08-28
UA111804C2 (uk)	2016-06-10
NO3052752T3 (fr)	2018-06-16
NL301155I2 (nl)	2022-02-23
PT2958921T (pt)	2017-11-20
EP2958921A1 (fr)	2015-12-30
RS56503B1 (sr)	2018-02-28
HRP20171599T1 (hr)	2017-12-01
ME03301B (fr)	2019-07-20
LT2958921T (lt)	2017-11-27
BR112015019634B1 (pt)	2022-09-20
IL240132A0 (en)	2015-09-24
TW201443055A (zh)	2014-11-16
PE20151764A1 (es)	2015-12-03
PH12015501779A1 (en)	2015-12-02
EP3290421B1 (fr)	2019-01-02
MD20150073A2 (ro)	2016-01-31
HUE037192T2 (hu)	2018-08-28
CN105008362A (zh)	2015-10-28
CY1121468T1 (el)	2020-05-29
HRP20171599T2 (hr)	2018-11-16
BR112015019634A2 (pt)	2019-12-17
GEP201606600B (en)	2017-01-10
LT3290421T (lt)	2019-02-25
LUC00261I2 (fr)	2025-04-25
AR094857A1 (es)	2015-09-02
NO2022004I1 (no)	2022-02-01
UY35337A (es)	2014-09-30
MD4735C1 (ro)	2021-07-31
CU20150078A7 (es)	2016-01-29
ZA201505454B (en)	2016-07-27
PT3290421T (pt)	2019-03-01
DK2958921T3 (da)	2017-11-06
IL240132B (en)	2020-09-30
ME02904B (fr)	2018-04-20
FR22C1006I2 (fr)	2023-01-27
EA201591255A1 (ru)	2016-03-31
DK3290421T3 (en)	2019-03-18
DOP2015000206A (es)	2016-02-15
LTC2958921I2 (fr)	2024-03-25
EP3290421A1 (fr)	2018-03-07
US9545405B2 (en)	2017-01-17
CL2015002303A1 (es)	2015-12-18
KR20150109434A (ko)	2015-10-01
US20150225408A1 (en)	2015-08-13
JP2017165762A (ja)	2017-09-21
CY1119502T1 (el)	2018-03-07
HUE041778T2 (hu)	2019-05-28
RS58245B1 (sr)	2019-03-29
CA2900703C (fr)	2017-11-28
NL301155I1 (fr)	2021-12-22
LTPA2022502I1 (fr)	2022-03-10
AU2014220357A1 (en)	2015-08-06
HUS2200003I1 (hu)	2022-02-28
EA027879B1 (ru)	2017-09-29
CR20150395A (es)	2015-09-23
MD4735B1 (ro)	2020-12-31
WO2014128591A1 (fr)	2014-08-28
AU2014220357B2 (en)	2017-04-27
CN105008362B (zh)	2017-06-06
CN107089985B (zh)	2019-06-07
SG11201505816UA (en)	2015-09-29
HK1213881A1 (zh)	2016-07-15
MA38347A1 (fr)	2017-10-31
JP2016509049A (ja)	2016-03-24
US9035074B2 (en)	2015-05-19
ES2713052T3 (es)	2019-05-17
FR22C1006I1 (fr)	2022-03-25
SI2958921T1 (sl)	2017-12-29

Publication	Publication Date	Title
CY2022003I1 (el)	2022-03-24	Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
IL258231A (en)	2018-05-31	New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
IL228590A0 (en)	2013-12-31	History of pyrrolo[3,2-d] pyrimidine as inhibitors of tropomyosin-linked kinases
SI2857404T1 (sl)	2017-11-30	Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji
SG11201600062RA (en)	2016-02-26	Pyrimidine derivatives as kinase inhibitors
IL254224A0 (en)	2017-10-31	7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
ZA201307839B (en)	2015-02-25	Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
EP3016953A4 (fr)	2017-03-01	Composés purinones comme inhibiteurs de kinase
EP3067356A4 (fr)	2017-03-22	Dérivé de pyrrolopyrimidine
EP2999702A4 (fr)	2017-01-11	Pyrazolopyrimidines substituées utiles comme inhibiteurs de kinases
IL243092A0 (en)	2016-02-01	New triazolo[d–4,5]pyrimidine histories
LT2948443T (lt)	2016-12-12	Nauji pirimidino dariniai kaip fosfodiesterazės 10 inhibitoriai (pde-10)
HK1224675A1 (en)	2017-08-25	Purinone compounds as kinase inhibitors